KCT0003797已完成未知
A multi-center, prospective, open-label, single-arm, 12-weeks, phase IV trial to evaluate the efficacy and safety of silodosin on nocturia for patients with benign prostatic hyperplasia
The Catholic University of Korea, Bucheon St. Mary's Hospital0 个研究点目标入组 126 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 126
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50(Year) 至 o Limit（—）
- 性别
- Male
入选标准
- •nocturia (=2 events/night) on 3-day voiding diary, an International Prostate Symptom Score (IPSS) =8, and a quality of life score =3
排除标准
- •prostate specific antigen >10 ng/ml, neurogenic bladder, bladder cancer, bladder stones, urethral stricture, acute urinary retention, urinary tract infection within one month, prostate cancer, a history of prostate surgery, use of an a-blocker or antimuscarinic agents within 2 weeks, or use of 5-a-reductase inhibitors within 6 months
研究者
相似试验
已完成
4 期
A Non-interventional, Post Marketing Surveillance (PMS) Study of Ryzodegâ?¢ (Insulin Degludec/ insulin aspart) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in IndiaCTRI/2015/12/006442ovo Nordisk India Private Ltd976
已完成
4 期
A study to evaluate the safety and efficacy of fixed dose combination of Silodosin and Dutasteride in men with benign prostatic hyperplasia.CTRI/2021/09/036299Akums Drugs Pharmaceuticals Limited200
进行中（未招募）
1 期
A study to evaluate the safety and potential therapeutic benefit of use of clazosentan in reversing cerebral vasospasm (a narrowing of blood vessels in the brain) in patients who have suffered a condition known as aneurysmal subarachnoid hemorrhage caused by bleeding onto the surface of the brain from a ruptured brain aneurysmcerebral vasospasmAneurysmal subarachnoid hemorrhage (aSAH)MedDRA version: 19.1Level: LLTClassification code 10047164Term: Vasospasm cerebralSystem Organ Class: 100000004852MedDRA version: 19.1Level: LLTClassification code 10042320Term: Subarachnoid hemorrhageSystem Organ Class: 100000004863EUCTR2015-002721-18-FIActelion Pharmaceuticals Ltd25
进行中（未招募）
1 期
A prospective, multi-center, open-label, single-arm, two- step phase II study of DURvalumab (MEDI4736) in patients WIth poor performance status as first-liNe treatment for advanced urothelial cancer: the DURWIN trialPatients aged 18 years or older with histologically or cytologically documented locally advanced (on the TNM staging system, T4b and any Nor any T and N2–3) or metastatic (M1, stage IV) urothelial carcinoma (including of the renal pelvis, ureter, urinary bladder, or urethra) who are eligibile to receive first-line systemic treatment and are judged to be ineligible for cisplatin treatment because of ECOG performance status= 2MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2018-003027-11-ITCONSORZIO ONCOTECH48
尚未招募
Unknown
Post-market clinical follow-up study for flowable gelatin haemostatic matrix kit in real-world patients to stop bleeding during surgeryCTRI/2024/06/068248Aegis Lifesciences Private Limited